Tags

Type your tag names separated by a space and hit enter

Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
Acta Obstet Gynecol Scand. 2004 Jul; 83(7):661-6.AO

Abstract

BACKGROUND

To compare the effect of hormone replacement therapy (HRT) using estrogen plus dydrogesterone or estrogen plus medroxyprogesterone acetate (MPA) on the risk factors for coronary heart disease (CHD) in postmenopausal women.

METHODS

A randomized, prospective 1-year clinical trial was designed. All of the postmenopausal women (n = 279) received sequential conjugated equine estrogen (CEE) at a dose of 0.625 mg/day for 25 days (days 1-25) of each month. These women were also randomly assigned to receive either dydrogesterone 10 mg/day (E + D group, n = 140) or MPA 5 mg/day (E + P group, n = 139) for 14 days (days 12-25) of each month. Serum biochemical markers, lipoproteins, plasma prothrombin time (PT), partial prothrombin time (PPT) and antithrombin III-antigen (ATIII-Ag) were analyzed at baseline, and after 6 and 12 months of treatment.

RESULTS

Liver function, renal function, PT and PPT did not change significantly during the 12-month trial. The E + D group had a more pronounced increase in high density lipoprotein cholesterol (HDL-C) than the E + P group (10.6% vs. 2.7%) after 12 months of treatment (p < 0.05). Both groups showed reduced concentrations of total cholesterol (T-CHO), low density lipoprotein cholesterol (LDL-C) and ATIII, whereas triglyceride (TG) was increased at the end of the trial (without intergroup difference).

CONCLUSIONS

Our study demonstrated a favorable effect on lipoprotein profiles with both hormone replacement therapy regimens. Dydrogesterone appears to be superior to medroxyprogesterone acetate from the perspective of modification of coronary heart disease risk factors.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15225192

Citation

Chang, Ting-Chen, et al. "Effect of Conjugated Equine Estrogen in Combination With Two Different Progestogens On the Risk Factors of Coronary Heart Disease in Postmenopausal Chinese Women in Taiwan: a Randomized One-year Study." Acta Obstetricia Et Gynecologica Scandinavica, vol. 83, no. 7, 2004, pp. 661-6.
Chang TC, Lien YR, Chen M, et al. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Acta Obstet Gynecol Scand. 2004;83(7):661-6.
Chang, T. C., Lien, Y. R., Chen, M., Cheng, S. P., Chen, R. J., & Chow, S. N. (2004). Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Acta Obstetricia Et Gynecologica Scandinavica, 83(7), 661-6.
Chang TC, et al. Effect of Conjugated Equine Estrogen in Combination With Two Different Progestogens On the Risk Factors of Coronary Heart Disease in Postmenopausal Chinese Women in Taiwan: a Randomized One-year Study. Acta Obstet Gynecol Scand. 2004;83(7):661-6. PubMed PMID: 15225192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. AU - Chang,Ting-Chen, AU - Lien,Yih-Ron, AU - Chen,Ming, AU - Cheng,Shao-Pei, AU - Chen,Ruey-Jien, AU - Chow,Song-Nan, PY - 2004/7/1/pubmed PY - 2004/8/3/medline PY - 2004/7/1/entrez SP - 661 EP - 6 JF - Acta obstetricia et gynecologica Scandinavica JO - Acta Obstet Gynecol Scand VL - 83 IS - 7 N2 - BACKGROUND: To compare the effect of hormone replacement therapy (HRT) using estrogen plus dydrogesterone or estrogen plus medroxyprogesterone acetate (MPA) on the risk factors for coronary heart disease (CHD) in postmenopausal women. METHODS: A randomized, prospective 1-year clinical trial was designed. All of the postmenopausal women (n = 279) received sequential conjugated equine estrogen (CEE) at a dose of 0.625 mg/day for 25 days (days 1-25) of each month. These women were also randomly assigned to receive either dydrogesterone 10 mg/day (E + D group, n = 140) or MPA 5 mg/day (E + P group, n = 139) for 14 days (days 12-25) of each month. Serum biochemical markers, lipoproteins, plasma prothrombin time (PT), partial prothrombin time (PPT) and antithrombin III-antigen (ATIII-Ag) were analyzed at baseline, and after 6 and 12 months of treatment. RESULTS: Liver function, renal function, PT and PPT did not change significantly during the 12-month trial. The E + D group had a more pronounced increase in high density lipoprotein cholesterol (HDL-C) than the E + P group (10.6% vs. 2.7%) after 12 months of treatment (p < 0.05). Both groups showed reduced concentrations of total cholesterol (T-CHO), low density lipoprotein cholesterol (LDL-C) and ATIII, whereas triglyceride (TG) was increased at the end of the trial (without intergroup difference). CONCLUSIONS: Our study demonstrated a favorable effect on lipoprotein profiles with both hormone replacement therapy regimens. Dydrogesterone appears to be superior to medroxyprogesterone acetate from the perspective of modification of coronary heart disease risk factors. SN - 0001-6349 UR - https://www.unboundmedicine.com/medline/citation/15225192/Effect_of_conjugated_equine_estrogen_in_combination_with_two_different_progestogens_on_the_risk_factors_of_coronary_heart_disease_in_postmenopausal_Chinese_women_in_Taiwan:_a_randomized_one_year_study_ L2 - https://doi.org/10.1111/j.0001-6349.2004.00217.x DB - PRIME DP - Unbound Medicine ER -